Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Vertex Pharmaceuticals Incorporated < Previous 1 2 3 4 Next > Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference June 10, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15 June 08, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA June 08, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions June 06, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress June 02, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers CRSP VRTX Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference May 31, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Suketu Upadhyay Elected to Vertex Board of Directors May 18, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies May 17, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Reports First Quarter 2022 Financial Results May 05, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes May 02, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Announce First Quarter 2022 Financial Results on May 5 April 21, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation April 20, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain March 31, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene March 26, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease March 22, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Reports Fourth Quarter 2021 and Full Year Financial Results January 26, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Announce Fourth Quarter 2021 Financial Results on January 26 January 18, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years January 11, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10 January 04, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis December 01, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene November 19, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11 November 12, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Reports Third-Quarter 2021 Financial Results November 02, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Announce Third-Quarter 2021 Financial Results on November 2 October 22, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC) October 19, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes October 18, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th September 13, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis August 26, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer August 04, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Reports Second-Quarter 2021 Financial Results July 29, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
